Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...

Q3 2024 Management View Revenue for Q3 FY2024 was JPY333.6 billion, with a year-over-year decrease of JPY3.2 billion. However, excluding a one-time payment of JPY25 billion recorded in Q1 FY2023, ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

Ironwood cuts 120 jobs (50% of workforce) amid apraglutide submission, Shionogi's RSV drug succeeds in Phase 2, and multiple companies announce deals and layoffs.

While most pharma companies have exited the antibiotics area, Japanese drugmaker Shionogi has stuck with it and has just expanded its pipeline with a deal to buy US biotech Qpex Biopharma.

Investors might want to bet on Shionogi & Co., Ltd. Unsponsored ADR (SGIOY), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings ...

Shionogi will receive $375 million to develop a long-acting protease inhibitor designed to prevent SARS-CoV-2 infection in people who are immune compromised.

Shionogi has expanded its partnership with its Alzheimer’s drug development partner Tetra Therapeutics, giving an option for a buyout of the US biotech ahead of a key trial milestone.

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced ...

European Commission authorises ViiV Healthcare’s long-acting injectable Vocabria plus Rekambys for HIV treatment in adolescents: London, UK Saturday, February 1, 2025, 11:00 Hrs ...

GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, has today announced that the European ...